CG Oncology, Inc. Common stock (CGON)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.65B
Last updated: Nov 17, 2026 at 11:05 AM ET
CG Oncology, Inc. Common stock (CGON) Earnings: Report Dates and Results
CG Oncology, Inc. Common stock (CGON) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, CG Oncology, Inc. Common stock reported EPS of -$0.64, above the -$0.86 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CGON has an expected report date of Feb 25, 2027.
Earnings History
Of the 12 quarters below that had an estimate, CGON beat 4 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $1.60M, down 4.2% from $1.67M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.64 | -$0.86 | -$0.96 - -$0.66 | +25.58% | Beat | N/A | 12 | 0 up, 10 down | Nov 6, 2026 | $1.60M |
| Jun 30, 2026 | -$0.90 | -$0.70 | -$0.73 - -$0.52 | -28.57% | Miss | N/A | 11 | 3 up, 6 down | Aug 6, 2026 | $1.16M |
| Mar 31, 2026 | -$0.71 | -$0.58 | -$0.66 - -$0.43 | -22.41% | Miss | N/A | 10 | 5 up, 0 down | May 8, 2026 | $1.08M |
| Dec 31, 2025 | -$0.51 | -$0.48 | N/A | -6.25% | Miss | N/A | 12 | 2 up, 5 down | Feb 27, 2026 | $2.32M |
| Sep 30, 2025 | -$0.57 | -$0.55 | -$0.63 - -$0.48 | -3.64% | Miss | N/A | 10 | 0 up, 1 down | Nov 14, 2025 | $1.67M |
| Jun 30, 2025 | -$0.54 | -$0.45 | -$0.50 - -$0.37 | -20.00% | Miss | N/A | 8 | 2 up, 1 down | Aug 8, 2025 | N/A |
| Mar 31, 2025 | -$0.45 | -$0.37 | -$0.51 - -$0.13 | -21.62% | Miss | N/A | 5 | N/A | May 13, 2025 | $52000 |
| Dec 31, 2024 | -$0.46 | -$0.45 | N/A | -2.22% | Miss | N/A | 1 | 1 up, 1 down | Mar 28, 2025 | $567000 |
| Sep 30, 2024 | -$0.30 | -$0.34 | -$0.57 - -$0.28 | +11.76% | Beat | N/A | 5 | 1 up, 0 down | Nov 14, 2024 | $43000 |
| Jun 30, 2024 | -$0.28 | -$0.31 | -$0.53 - -$0.23 | +9.68% | Beat | N/A | 5 | 1 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.36 | -$0.15 | N/A | -140.00% | Miss | N/A | N/A | N/A | May 9, 2024 | $529000 |
| Dec 31, 2023 | -$0.33 | -$0.67 | N/A | +50.61% | Beat | N/A | N/A | N/A | Mar 26, 2024 | $1000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.07, after -$1.40 the year before. It was -$0.33 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.07 | N/A |
| Dec 31, 2024 | -$1.40 | N/A |
| Dec 31, 2023 | -$0.33 | N/A |
Frequently Asked Questions About CGON
When is CG Oncology, Inc. Common stock's next earnings date?
CG Oncology, Inc. Common stock's next earnings report is expected for Feb 25, 2027.
Did CGON beat earnings estimates last quarter?
Yes. CG Oncology, Inc. Common stock reported EPS of -$0.64 for the quarter ended Sep 30, 2026, above the -$0.86 estimate, a 25.58% surprise.
What EPS do analysts expect from CGON next quarter?
The consensus EPS estimate for CG Oncology, Inc. Common stock for the quarter ending Dec 31, 2026 is -$0.84 from 16 analysts, with estimates from -$1.01 to -$0.62.
How often does CGON beat earnings estimates?
CG Oncology, Inc. Common stock beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -9.89%.
CGON pages: Overview, Earnings, Forecast, Financials, Competitors